InvestorsHub Logo
Followers 15
Posts 1528
Boards Moderated 1
Alias Born 10/26/2015

Re: None

Thursday, 07/14/2016 4:02:10 AM

Thursday, July 14, 2016 4:02:10 AM

Post# of 279
Juno Therapeutics (JUNO +1.68%) surged 33% in after-hours trading after the FDA removed the clinical hold on Juno's Phase 2 study of JCAR015 to treat lymphoblastic leukemia.